BioCentury
ARTICLE | Company News

Dainippon Sumitomo cancer news

August 27, 2012 7:00 AM UTC

Dainippon said it will establish the DSP Cancer Institute for cancer R&D. Chiang Li, who is president, CEO and CMO of Dainippon's Boston Biomedical Inc. subsidiary, will head the institute, which Dainippon said will be independent of its research division. Li is also head of global oncology for Dainippon. The pharma also said it strengthened functions of the Global Oncology Business Development Office to provide centralized management of cancer R&D and management of the institute. Additionally, Boston Biomedical plans to establish this year a global oncology R&D center in Cambridge, Mass., with about 100 employees. The pharma could not be reached for details. ...